Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
MASS 
908 Devices Inc (MASS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/19/2026: MASS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 249.01M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 4 | Beta 0.49 | 52 Weeks Range 1.92 - 9.34 | Updated Date 02/19/2026 |
52 Weeks Range 1.92 - 9.34 | Updated Date 02/19/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -6.35% | Operating Margin (TTM) -40.1% |
Management Effectiveness
Return on Assets (TTM) -16.43% | Return on Equity (TTM) -54.42% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 127194427 | Price to Sales(TTM) 3.83 |
Enterprise Value 127194427 | Price to Sales(TTM) 3.83 | ||
Enterprise Value to Revenue 1.97 | Enterprise Value to EBITDA -3.15 | Shares Outstanding 36192978 | Shares Floating 22107757 |
Shares Outstanding 36192978 | Shares Floating 22107757 | ||
Percent Insiders 8.99 | Percent Institutions 89.36 |
Upturn AI SWOT
908 Devices Inc
Company Overview
History and Background
908 Devices Inc. was founded in 2012 as a spin-off fromstratech. The company specializes in developing and commercializing high-pressure mass spectrometry (HPMS) technology. Significant milestones include the development of their first commercial product, the MX908, in 2016, and subsequent introductions of the ZipChip and Rebel devices, expanding their product portfolio and market reach into areas like life sciences and advanced materials.
Core Business Areas
- High-Pressure Mass Spectrometry (HPMS): 908 Devices develops and manufactures advanced mass spectrometry instruments that leverage their proprietary High-Pressure Mass Spectrometry (HPMS) technology. This technology enables rapid, field-deployable, and highly sensitive chemical analysis.
- Life Sciences: This segment focuses on providing HPMS solutions for drug discovery, development, and quality control in the pharmaceutical and biotechnology industries. Products in this area help accelerate research and improve efficiency.
- Public Safety and Defense: 908 Devices offers portable and robust analytical instruments for identifying chemical threats, explosives, narcotics, and other hazardous materials in real-time for first responders and military personnel.
- Materials Science and Industrial Applications: The company's technology is also applied to analyze and characterize materials in various industrial settings, supporting research, quality assurance, and process optimization.
Leadership and Structure
As a publicly traded company, 908 Devices Inc. operates with a Board of Directors and a management team responsible for its strategic direction and operational execution. Key leadership roles typically include a Chief Executive Officer, Chief Financial Officer, and heads of various business units and R&D. The exact current leadership can be found in their latest SEC filings.
Top Products and Market Share
Key Offerings
- MX908: A portable, high-performance mass spectrometer designed for rapid, on-site detection and identification of trace chemicals, including explosives, narcotics, and chemical warfare agents. Competitors include companies like Smiths Detection and FLIR Systems in the portable detection market. Market share data is not publicly disclosed for this specific product.
- ZipChip: A liquid chromatography-mass spectrometry (LC-MS) solution that integrates directly with existing mass spectrometers, enabling rapid sample introduction and analysis of small molecules. This product is aimed at the drug discovery and development market. Competitors in the broader LC-MS market include Agilent Technologies, Thermo Fisher Scientific, and Waters Corporation. Specific market share for ZipChip is not disclosed.
- Rebel: A benchtop mass spectrometry device for biopharmaceutical process development and characterization, focusing on protein and peptide analysis. Competitors include major players in the biopharmaceutical analytical instrument market such as Waters, Thermo Fisher Scientific, and SCIEX. Specific market share for Rebel is not disclosed.
Market Dynamics
Industry Overview
908 Devices operates within the highly competitive analytical instrumentation market, which is driven by innovation, demand for higher sensitivity, faster analysis, and increased portability. Key sectors include life sciences (pharmaceuticals, biotech), public safety, defense, and industrial applications. The market is characterized by significant R&D investment and a need for regulatory compliance.
Positioning
908 Devices positions itself as a provider of unique, high-performance analytical solutions that offer advantages in speed, portability, and sensitivity due to its proprietary HPMS technology. Their competitive advantage lies in their specialized technology, enabling applications where traditional instruments may be too slow, bulky, or expensive. They aim to address unmet needs in rapid, on-site chemical analysis.
Total Addressable Market (TAM)
The TAM for analytical instruments is substantial, spanning multiple industries. For instance, the global mass spectrometry market is projected to reach tens of billions of dollars. 908 Devices targets specific niches within this larger market, such as portable chemical detection and biopharmaceutical analysis, where they aim to capture significant market share through their differentiated technology.
Upturn SWOT Analysis
Strengths
- Proprietary HPMS Technology: Offers unique performance advantages in speed, sensitivity, and portability.
- Diverse Application Areas: Technology is applicable across multiple high-value markets (life sciences, public safety, defense).
- Experienced Management Team: Leadership with a strong background in mass spectrometry and commercialization.
- Patented Innovations: Strong intellectual property portfolio protecting their core technology.
Weaknesses
- Relatively Smaller Market Share: Compared to established giants in the analytical instrument industry.
- Reliance on Key Technologies: Future growth is heavily dependent on the continued development and adoption of HPMS.
- Manufacturing Scale: May face challenges scaling manufacturing to meet rapidly growing demand compared to larger competitors.
- Brand Recognition: As a relatively younger company, may have lower brand recognition in certain segments.
Opportunities
- Expansion in Life Sciences: Growing demand for faster drug discovery and development tools.
- Increasing Security Needs: Rising global security concerns drive demand for advanced chemical detection.
- Emerging Markets: Potential for international expansion and adoption of their technology.
- Technological Advancements: Further development of HPMS capabilities for new applications.
Threats
- Intense Competition: From large, well-established analytical instrument manufacturers.
- Technological Obsolescence: Rapid pace of innovation can render existing technologies outdated.
- Economic Downturns: Can reduce capital expenditure by customers in key industries.
- Regulatory Changes: Impacting the use or approval of their instruments in certain applications.
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Agilent Technologies (A)
- Waters Corporation (WAT)
- Smiths Group plc (SMIN.L) - focused on detection segments
Competitive Landscape
908 Devices competes with much larger, established players with broader product portfolios and deeper market penetration. Its advantage lies in its specialized, proprietary technology that offers unique benefits. However, it faces challenges in competing on scale, brand recognition, and breadth of offerings. Its success depends on continued technological differentiation and its ability to capture niche markets effectively.
Growth Trajectory and Initiatives
Historical Growth: 908 Devices has demonstrated consistent revenue growth over its history, driven by the successful commercialization of its HPMS technology and expansion into new market segments. This growth has been fueled by product innovation and increasing adoption rates.
Future Projections: Future growth projections are typically based on analyst estimates and the company's strategic outlook. These projections often involve continued expansion in life sciences, increased penetration in public safety, and the development of new applications for their technology. Specific growth rates vary based on analyst models and market conditions.
Recent Initiatives: Recent initiatives likely include the expansion of their sales and marketing teams, continued investment in R&D for next-generation products, strategic partnerships, and efforts to enhance manufacturing capabilities to support increasing demand.
Summary
908 Devices Inc. is a promising technology company with a strong foundation in proprietary High-Pressure Mass Spectrometry (HPMS). Its innovative approach offers significant advantages in speed and portability for chemical analysis, catering to high-growth sectors like life sciences and public safety. While facing stiff competition from larger players, the company's unique technology and diverse application potential position it for continued expansion. However, sustained investment in R&D and manufacturing scale will be crucial to maintain its competitive edge and achieve profitability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Relations Websites
- Reputable Financial News Outlets
- Industry Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 908 Devices Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2020-12-18 | Co-Founder, CEO, President & Director Dr. Kevin J. Knopp Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 246 | Website https://908devices.com |
Full time employees 246 | Website https://908devices.com | ||
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices for use in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as process fingerprint data to support large-scale efforts in predictive bioprocess modeling. The company's products comprise Maven, an on-line device for bioprocess monitoring and control; Trace C2, an on-line monitoring of methanol or ethanol and control of substrate feeding in fermentation processes; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.